{
    "medicine_id": "a5570295bf9439d370a6e617e5b826699da3915a",
    "platform_id": "DB13985",
    "metadata": {
        "name": "Lutathera 10 mCi 1mL Injection",
        "composition": "10 mCi 1mL Lutetium Lu 177 dotatate",
        "clinical_particulars": {
            "therapeutic_indications": "Indicated for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors GEP NETs including foregut midgut and hindgut neuroendocrine tumors in adults FDA Label",
            "contraindications": {
                "disease": "While carcinogenicity and mutagenicity studies have not been conducted with lutetium 177 dotatate radioisotope is considered a carcinogen and mutagen No fertility studies have been performed FDA Label In repeat dose toxicity studies of rats pancreatic acinar apoptosis occurred at lutetium Lu 175 dotatate doses 5 mg kg Pancreatic acinar cell atrophy also occurred in repeat dose toxicology studies in dogs at doses 500 mg kg FDA Label",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Clinically significant myelosuppression occurred in less than 10 of patients in the Lutetium Lu 177 dotatate 177Lu Dotatate group in one clinical trial A31697 According to an open label study involving 20 patients with somatostatin receptor positive midgut carcinoid tumors the treatment with did not result in any large changes in the mean QTc interval i e 20 ms FDA Label Due to high expression of SSTR2 pancreas was the primary target in animal studies using a non radioactive form of lutetium Lu 177 dotatate lutetium Lu 175 dotatate FDA Label",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00104",
                        "description": "The therapeutic efficacy of Lutetium Lu 177 dotatate can be decreased when used in combination with Octreotide"
                    },
                    {
                        "drugbank-id": "DB04894",
                        "description": "The therapeutic efficacy of Lutetium Lu 177 dotatate can be decreased when used in combination with Vapreotide"
                    },
                    {
                        "drugbank-id": "DB06663",
                        "description": "The therapeutic efficacy of Lutetium Lu 177 dotatate can be decreased when used in combination with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB06791",
                        "description": "The therapeutic efficacy of Lutetium Lu 177 dotatate can be decreased when used in combination with Lanreotide"
                    },
                    {
                        "drugbank-id": "DB09099",
                        "description": "The therapeutic efficacy of Lutetium Lu 177 dotatate can be decreased when used in combination with Somatostatin"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}